专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2130817A1 Polymerizable Type II photoinitiators and curable compositions 有权
标题翻译： Polymerisierbare Typ II-Fotoinitiatoren undhärtbareZusammensetzungen
公开(公告)号：EP2130817A1
公开(公告)日：2009-12-09
申请号：EP08104269.9
申请日：2008-06-05
申请人： AGFA Graphics NV
发明人： Loccufier, Johan , Van Luppen, Jaymes
IPC分类号： C07C219/08 , C07D219/14 , C07D295/18 , C07D311/86 , C09D11/00
CPC分类号： C07D335/16 , C07C217/22 , C07C219/08 , C07C219/14 , C09D11/101 , C09D11/322
摘要： A polymerizable Type II photoinitiator according to Formula (I):

wherein:
A represents a Norrish Type II initiating group;
L represents a divalent linking group positioning the Norrish Type II initiating group A and the CR2R3-group in a 1-5 to a 1-8 position wherein position 1 is defined as the first atom in the aromatic or alicyclic ring of A to which L is covalently bonded and the position 5 to 8 is defined as the carbon atom of the CR2R3-group to which L is covalently bonded, with the proviso that L does not contain an amine. Radiation curable compositions and inks including the multifunctional Type II photoinitiator are also disclosed.
摘要翻译：根据式（I）的可聚合II型光引发剂：其中：A表示Norrish II型引发基团; L代表将Norrish II型引发基团A和CR 2 R 3基团定位在1-5至1-8位置的二价连接基团，其中位置1定义为A的芳族或脂环族环中的第一个原子，其中L 共价键合，位置5至8定义为L共价键合的CR 2 R 3基团的碳原子，条件是L不含胺。还公开了包括多功能II型光引发剂的可辐射固化组合物和油墨。

2. 发明授权

EP1138745B1 ORGANIC ELECTROLUMINESCENT ELEMENT 有权
标题翻译： ELEKTROLUMINESZIERENDE，ORGANISCHE VORRICHTUNG
公开(公告)号：EP1138745B1
公开(公告)日：2007-03-28
申请号：EP00962882.7
申请日：2000-09-27
申请人： IDEMITSU KOSAN COMPANY LIMITED
发明人： TAGAMI, Sanae , IKEDA, Hidetsugu , HOSOKAWA, Chishio , ARAKANE, Takashi
IPC分类号： C09K11/06 , C07C13/62 , C07C211/61 , C07C217/92 , C07C217/94 , C07C229/74 , C07C255/58 , C07D295/12 , C07D219/14 , C07D223/26 , C07D223/14 , C07D221/18 , C07D279/24 , H05B33/14 , H05B33/22
CPC分类号： H01L51/0056 , C07C13/62 , C07C13/70 , C07C211/61 , C07C217/92 , C07C217/94 , C07C229/68 , C07C255/42 , C07C255/58 , C07C2601/14 , C07C2603/54 , C07D219/14 , C07D223/14 , C07D223/26 , C07D223/28 , C07D279/26 , C07D295/02 , C07D295/135 , C07D295/155 , C07D471/06 , C09K11/06 , C09K2211/1007 , C09K2211/1011 , C09K2211/1014 , C09K2211/1029 , C09K2211/1037 , H01L51/0054 , H01L51/0059 , H01L51/006 , H01L51/0081 , H01L51/5012 , H01L51/5048 , H05B33/14 , Y10S428/917
摘要： An organic electroluminescent element which has a high color purity, high luminescent efficiency, and long life and emits a red color; and a novel compound. The organic electroluminescent element comprises at least one pair of electrodes and an organic layer interposed therebetween, and is characterized in that the organic layer contains a compound comprising a fluoranthene-containing skeleton which has been substituted at least by an amine or alkenyl group.
摘要翻译：具有优异的颜色纯度和高发光效率的有机电致发光元件具有使用寿命长并发出红光，并具有这些特性的新化合物。有机电致发光器件包括设置在至少一对电极之间的有机层，其中有机层包含具有至少被胺基或烯基取代的荧蒽骨架结构的化合物。

3. 发明公开

EP0804074A4 TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS 失效
标题翻译：用抗病毒药剂解的治疗红细胞
公开(公告)号：EP0804074A4
公开(公告)日：1999-12-08
申请号：EP95939848
申请日：1995-11-08
申请人： CERUS CORP
发明人： COOK DAVID , WOLLOWITZ SUSAN , NIERO AILEEN
IPC分类号： C12Q1/00 , A61K31/47 , A61K31/473 , A61L2/00 , A61P31/12 , C07D219/12 , C07D219/14 , C07D493/04 , C12N1/20 , C12N5/06 , C12N5/08 , C12N7/04 , C12N7/06 , C12Q1/68 , A01N1/02 , A01N63/00 , C07D311/02
CPC分类号： C07D493/04 , A61K35/16 , A61L2/0088 , A61L2/18 , C07D219/12 , C12N7/00 , C12N7/04 , C12N2730/10163 , C12N2740/16063 , C12N2795/18163
摘要： Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.

4. 发明公开

EP0889037A1 NITROGENOUS TRICYCLIC COMPOUNDS AND DRUGS COMPRISING THE SAME 失效
标题翻译：医疗器械制造商维吾尔自行车
公开(公告)号：EP0889037A1
公开(公告)日：1999-01-07
申请号：EP97907297.2
申请日：1997-03-13
申请人： Eisai Co., Ltd.
发明人： MIYAMOTO, Mitsuaki , YOSHIUCHI, Tatsuya , SATO, Keizo , KAINO, Makoto , TANAKA, Masayuki , SOEJIMA, Motoharu , MORIYA, Katsuhiro , SAKUMA, Yoshinori , YAMADA, Koji , HARADA, Kokichi , NISHIZAWA, Yukio , KOBAYASHI, Seiichi , OKITA, Makoto , KATAYAMA, Koichi
IPC分类号： C07D219/14 , C07D243/38 , C07D279/24 , C07D279/34 , C07D417/06 , C07D417/12 , C07D417/14 , A61K31/54 , A61K31/645
CPC分类号： C07D417/06 , C07D279/22 , C07D279/24 , C07D417/12 , C09B21/00 , C09B57/08
摘要： To provide a novel phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative efficacious against diseases in which histamine, leukotrienes, etc. participate.
A phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative represented by the following formula are efficacious in preventing or treating diseases in which chemical mediators such as histamine and leukotrienes participate, for example, asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, gastrointestinal allergy and food allergy.
A nitrogen-containing tricyclic compound represented by the following formula (I), a hydrate thereof or a pharmacologically acceptable salt thereof:
(wherein D represents alkylene, etc.)
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are the same or different from each other and each represents hydrogen, hydroxy, cyano, nitro, optionally substituted carbamoyl, halogeno, optionally halogenated lower alkyl, etc.; Z represents -S-, -SO-, -SO 2 -, =NO-substituent, -NC(O)- or =NN-substituent; and Q represents, for example, -NR 20 R 21 (wherein R 20 and R 21 are the same or different from each other and each represents hydrogen, optionally halogenated lower alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, or R 20 and R 21 may form together with the nitrogen atom to which they are bonded a 3- to 8-membered ring).
摘要翻译：提供对组胺，白三烯等参与的疾病有效的新型吩噻嗪，吖啶酮，吖啶酮肟，吖啶酮腙和二苯并二氮杂衍生物。由下式表示的吩噻嗪，吖啶酮，吖啶酮肟，吖啶酮腙和二苯并二氮杂衍生物可有效预防或治疗化学介质如组胺和白三烯参与的疾病，例如哮喘，过敏性鼻炎，特应性皮炎，荨麻疹，干草发烧，胃肠道过敏和食物过敏。由下式（I）表示的含氮三环化合物，其水合物或其药理学上可接受的盐：（其中D表示亚烷基等，其中R 1，R 2， R 3，R 4，R 5，R 6，R 7和R 8彼此相同或不同，各自表示氢，羟基，氰基，硝基，任选取代的氨基甲酰基，卤代，任选卤代的低级烷基等; Z表示-S-，-SO-，-SO 2 - ，= NO-取代基，-NC（O） - 或= N - 取代基; Q表示例如-NR R 20和R 21彼此相同或不同，各自表示氢，任选卤代的低级烷基，任选取代的芳基，任选取代的芳烷基，任选取代的杂芳基或任选取代的杂芳基烷基或R 20和R 21可以与它们所键合的氮原子一起形成3-至8-元环）。

5. 发明公开

EP4194089A2 CATALYST SYSTEM FOR SUZUKI CROSS-COUPLING REACTIONS COMPRISING A PHOTOREDOX COMPONENT 无效
公开(公告)号：EP4194089A2
公开(公告)日：2023-06-14
申请号：EP22178854.0
申请日：2022-06-14
申请人： Heraeus Deutschland GmbH & Co. KG , New Iridium, Inc.
发明人： Walter, Philipp , Kolvenbach, Robin , Gock, Michael , Elder, William Zachary , Federico, Celia , Boston, David J. , Vora, Harit , Cutcliffe, Brent , Lim, Chern-Hooi
IPC分类号： B01J31/02 , B01J31/18 , B01J31/22 , B01J37/34 , C07D209/58 , C07D219/14 , C07D265/38
摘要： The present invention relates to a composition, comprising
- a palladium compound which is a palladium salt or a palladium complex or a mixture thereof, and
- a polycyclic compound of Formula (I), (II) or (III):

6. 发明公开

EP3969438A1 OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE 审中-公开
公开(公告)号：EP3969438A1
公开(公告)日：2022-03-23
申请号：EP20730867.7
申请日：2020-05-15
申请人： Stingthera, Inc.
发明人： ALLEN, Bryce K. , CHAMBERLAIN, Brian T. , DWIGHT, Timothy A. , HUANG, Huang , LIN, Zhixiong , MARINO, Kristen A. , NIU, Deqiang , SHECHTER, Sharon , SWANN, Steven
IPC分类号： C07D219/14 , A61K31/473 , A61P25/00 , A61P29/00 , A61P31/04 , A61P31/10 , A61P35/00 , A61P37/00

7. 发明授权

EP3067345B1 ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS 有权转让
公开(公告)号：EP3067345B1
公开(公告)日：2018-09-05
申请号：EP16163154.4
申请日：2010-11-12
申请人： Siemens Healthcare Diagnostics Inc.
发明人： Natrajan, Anand , Sharpe, David , Jiang, Qingping
IPC分类号： C07D219/04 , C07D219/14 , C07D401/12 , G01N33/543
CPC分类号： G01N33/54393 , C07D219/04 , C07D219/14 , C07D401/12 , C09B15/00 , Y10T436/13
摘要： Hydrophilic, chemiluminescent acridinium compounds of formula (II) containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.

8. 发明公开

EP0595365A1 Pharmaceutical composition for the treatment of underlying nonpharmacologically induced nervous system cholinergic deficit state comprising monoamine acridine derivatives 失效
标题翻译：用于处理含单aminakridin衍生物胆碱能神经系统的非pharmacologischer Unsprungender缺乏症的药物组合物。
公开(公告)号：EP0595365A1
公开(公告)日：1994-05-04
申请号：EP93117982.4
申请日：1987-09-28
申请人： Summers, William Koopmans
发明人： Summers, William Koopmans
IPC分类号： A61K31/47 , A61K31/495 , C07D401/06 , C07D219/14
CPC分类号： A61K31/00 , A61K31/47 , A61K31/495 , C07D219/10
摘要： A pharmaceutical composition for treatment of underlying nonpharmacologically induced central or peripheral nervous system cholinergic deficit state in humans comprising a monoamine acridine derivative of the formula:

wherein R₁ represents hydrogen, hydroxy, methyl, methoxy, ethyl or ethoxy; R₁ and R₂ together may form a double bond, R₃ and R₄ together may form a double bond, or R₁, R₂, R₃ and R₄ are all hydrogen; R₅ represents hydrogen, hydroxy, methoxy or ethoxy; R₆ represents hydrogen, hydroxy, methoxy or ethoxy; and R₇ is without a substituent or R₇ represents an oxygen atom, a C₁-C₂₀ alkyl radical or a radical selected from the group consisting of
-R-N(R)₂,

wherein each R is independently selected from C₁-C₂₀ alkyl; or a pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable inert carrier therefor; with the provisos that the monoamine acridine derivative is a compound in which (i) if R₁, R₂, R₃, R₄, R₅ and R₆ are each hydrogen, then R₇ cannot be without a substituent, (ii) if R₁ and R₂ together form a double bond, R₃ and R₄ together form a double bond and R₅ and R₆ are each hydrogen, then R₇ cannot be without a substituent, and (iii) if R₃ and R₄ together form a double bond and R₇ is without a substituent, then R₁ cannot be a hydrogen atom is provided.
摘要翻译：用于治疗的药物组合物底层nonpharmacologically诱导人类，包括下式的一元胺衍生物吖中枢或外周神经系统胆碱能缺乏状态： worin氢R1 darstellt，羟基，甲基，甲氧基，乙基或乙氧基; R1和R2可一起形成一个双键，R 3和R 4一起可以形成双键，或R1，R2，R3和R4都是氢; R5氢darstellt，羟基，甲氧基或乙氧基; 氢R6 darstellt，羟基，甲氧基或乙氧基; 和R 7是不具有取代基或氧原子的R7 darstellt，一个C1-C20烷基或基团选自下组的R-N（R）2中选择， worin每个R是unabhängig从C1-C20烷基; 或其药学上可接受的盐，和药学上可接受的隋性载体; 与DASS死单胺吖啶衍生物，条件是，其中（i）如果R1，R2，R3，R4，R5和R6各自为氢，则R 7不能是化合物不具有取代基的，（ⅱ）如果R 1和R 2一起形成一个双键，R 3和R 4一起形成双键且R 5和R 6各自为氢时，则R 7不能没有取代基，以及（iii）如果R 3和R 4一起形成双键，R 7是不具有取代基时，则R 1不能是提供一种氢原子。

10. 发明公开

EP3618134A1 LIGHT-EMITTING ELEMENT 审中-实审
公开(公告)号：EP3618134A1
公开(公告)日：2020-03-04
申请号：EP18792310.7
申请日：2018-04-20
申请人： Sumitomo Chemical Company Limited
发明人： SASADA, Toshiaki , OKAMURA, Rei
IPC分类号： H01L51/50 , C07C211/61 , C07D219/14 , C07D265/38 , C07D307/91 , C07D333/76 , C07D403/10 , C07D409/14 , C07D417/10 , C07F15/00 , C08G61/12 , C09K11/06
摘要： To provide a light emitting device excellent in luminance life.
A light emitting device having an anode, a cathode, a first organic layer disposed between the anode and the cathode and a second organic layer disposed between the anode and the cathode, wherein
the first organic layer is a layer containing a compound represented by the formula (C-1), and
the second organic layer is a layer containing a compound represented by the formula (C-1) and a cross-linked body of a crosslinkable material:

[wherein,
Ring R 1C and Ring R 2C represent an aromatic hydrocarbon ring or an aromatic hetero ring.
R C represents an oxygen atom, a sulfur atom or a group represented by the formula (C'-1).]

[wherein,
Ring R 3C and Ring R 4C represent an aromatic hydrocarbon ring or an aromatic hetero ring.
R C' represents a carbon atom, a silicon atom, a germanium atom, a tin atom or a lead atom.]

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式